Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

INSULET Aktie

 >INSULET Aktienkurs 
178.5 EUR    -0.1%    (TradegateBSX)
Ask: 178.9 EUR / 55 Stück
Bid: 175.35 EUR / 57 Stück
Tagesumsatz: 15 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
INSULET Aktie über LYNX handeln
>INSULET Performance
1 Woche: -2,6%
1 Monat: -14,3%
3 Monate: -25,7%
6 Monate: -32,2%
1 Jahr: -23,2%
laufendes Jahr: -26,9%
>INSULET Aktie
Name:  INSULET CORP. DL -,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45784P1012 / A0MQX8
Symbol/ Ticker:  GOV (Frankfurt) / PODD (NASDAQ)
Kürzel:  FRA:GOV, ETR:GOV, GOV:GR, NASDAQ:PODD
Index:  -
Webseite:  https://www.insulet.com/
Profil:  Insulet Corporation is a medical device company that develops, manufactures, and sells innovative insulin delivery systems, primarily through its Omnipod product platform, for people with insulin-dependent diabetes worldwide. The Omnipod offers a tub..
>Volltext..
Marktkapitalisierung:  12626.33 Mio. EUR
Unternehmenswert:  12869.55 Mio. EUR
Umsatz:  2346.15 Mio. EUR
EBITDA:  508.53 Mio. EUR
Nettogewinn:  214.07 Mio. EUR
Gewinn je Aktie:  3.04 EUR
Schulden:  867.96 Mio. EUR
Liquide Mittel:  620.37 Mio. EUR
Operativer Cashflow:  493.19 Mio. EUR
Bargeldquote:  1.05
Umsatzwachstum:  15.23%
Gewinnwachstum:  -47.93%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  INSULET
Letzte Datenerhebung:  04.04.26
>INSULET Kennzahlen
Aktien/ Unternehmen:
Aktien: 70.4 Mio. St.
Frei handelbar: 99.55%
Rückkaufquote: 0.18%
Mitarbeiter: 5400
Umsatz/Mitarb.: 0.43 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 75.04%
Bewertung:
KGV: 58.61
KGV lG: 31.82
KUV: 5.76
KBV: 9.53
PEG-Ratio: -
EV/EBITDA: 25.31
Rentabilität:
Bruttomarge: 72.17%
Gewinnmarge: 9.12%
Operative Marge: 17.5%
Managementeffizenz:
Gesamtkaprendite: 7.87%
Eigenkaprendite: 18.12%
>INSULET Peer Group
Gesundheit, Diabetes- & Adipositas- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
03.04.26 - 17:30
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
01.04.26 - 15:03
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky (PR Newswire)
 
Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 1, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026,......
01.04.26 - 13:03
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 (Business Wire)
 
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its...
30.03.26 - 14:36
Insulet Appoints Mike Panos as Chief Commercial Officer (Business Wire)
 
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. “We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes,” said Ashley McEvoy, Insulet President and Chief Executive Officer. “We are implementing thoughtful strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in bui...
25.03.26 - 14:03
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky (PR Newswire)
 
Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, March 25, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12,......
21.03.26 - 13:18
Is Insulet Stock Underperforming the Dow? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
20.03.26 - 18:45
Should You Continue to Hold Insulet Stock in Your Portfolio? (Zacks)
 
PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could challenge its near-term performance....
20.03.26 - 18:30
Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound? (Zacks)
 
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....
18.03.26 - 22:31
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky (PR Newswire)
 
Insulet CEO Called Omnipod 5 "Reliable" and a "Favorite Pump" on February 18 -- Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective Pods NEW YORK, March 18, 2026 /PRNewswire/ -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told......
14.03.26 - 16:51
EXCLUSIVE: Just 5 Female CEOs In A 50-Stock ETF — C-Suite Execs Explain The Leadership Gap In Corporate America (Benzinga)
 
-link data-ticker=GOOGL data-exchange=NASDAQ href=https://www.benzinga.com/quote/GOOGL target=_blank rel=noopener>(NASDAQ: GOOGL), One week after we celebrated the International Women's day, here is a stark reminder how the C-suite remains underrepresented by women.Data from a leadership-focused ETF underscores how uncommon female leadership remains among large U.S. companies. The Wedbush ReturnOnLeadership U.S. Large-Cap ETF (ARCA: EXEQ) universe of 50 companies, only about 10% are led by women CEOs. Those include Jayshree Ullal of Arista Networks Inc (NYSE: ANET), Lori Koch of DuPont de Nemours Inc (NYSE: DD), Martina Cheung of S&P Global Inc (NYSE: SPGI), Ashley McEvoy of Insulet Corp (NASDAQ: PODD) and Debra Cafaro of Ventas Inc (NYSE: VTR). The ETF tracks companies ranked through a leadership execution framework developed by Indiggo. Janeen Gelbart, co-founder and CEO of the firm, said the methodology evaluates corporate leadership broadly rather than focusing on individual executives. ...
13.03.26 - 17:48
Stocks making the biggest moves midday: Adobe, Ulta Beauty, Insulet, Klarna, Once Upon a Farm & more (CNBC)
 
These are some of the stocks posting the largest moves midday....
13.03.26 - 13:42
Insulet recalling certain defective Omnipod insulin delivery devices (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.26 - 14:01
Insiderhandel: Aufsichtsrat kauft Aktien von Insulet im Wert von 499847 USD (Insiderkauf)
 
Minogue, Michael R. - Aufsichtsrat - Tag der Transaktion: 2026-02-25...
23.02.26 - 16:02
Insiderhandel: President and CEO kauft Aktien von Insulet im Wert von 1029205 USD (Insiderkauf)
 
Mcevoy, Ashley - Vorstand - Tag der Transaktion: 2026-02-20...
19.02.26 - 16:00
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
 
Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook....
18.02.26 - 23:00
Insulet outlines 21%–23% Omnipod revenue growth for 2026 with operating margin expansion, driven by global adoption and product innovation (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.02.26 - 18:24
Insulet gains after Q4 print as outlook tops consensus (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.02.26 - 16:45
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
 
The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....
18.02.26 - 16:00
Insulet (PODD) Tops Q4 Earnings and Revenue Estimates (Zacks)
 
Insulet (PODD) delivered earnings and revenue surprises of +4.87% and +2.15%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
18.02.26 - 15:42
Insulet übertrifft Umsatzerwartungen in Q4 2025 – Aktie legt deutlich zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!